Correlation Engine 2.0
Clear Search sequence regions

  • CDKN2A (1)
  • cpg island (1)
  • glioma (10)
  • humans (1)
  • IDH (13)
  • patients (4)
  • prognostic (1)
  • still (1)
  • Sizes of these terms reflect their relevance to your search.

    Mutations in the pivotal metabolic isocitrate dehydrogenase (IDH) enzymes are recognized to drive the molecular footprint of diffuse gliomas, and patients with IDH mutant gliomas have overall favorable outcomes compared to patients with IDH wild-type tumors. However, survival still varies widely among patients with IDH mutated tumors. Here, we aimed to characterize molecular signatures that explain the range of IDH mutant gliomas. By integrating matched epigenome-wide methylome, transcriptome, and global metabolome data in 154 patients with gliomas, we identified a group of IDH mutant gliomas with globally altered metabolism that resembled IDH wild-type tumors. IDH-mutant gliomas with altered metabolism have significantly shorter overall survival from their IDH mutant counterparts that is not fully accounted for by recognized molecular prognostic markers of CDKN2A/B loss and glioma CpG Island Methylator Phenotype (GCIMP) status. IDH-mutant tumors with dysregulated metabolism harbored distinct epigenetic alterations that converged to drive proliferative and stem-like transcriptional profiles, providing a window to target novel dependencies in gliomas. © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.


    Farshad Nassiri, Andrew Ajisebutu, Vikas Patil, Yasin Mamatjan, Jeff Liu, Justin Z Wang, Mathew R Voisin, Romina Nejad, Sheila Mansouri, Shirin Karimi, Ankur Chakravarthy, Eric Chen, Daniel D De Carvalho, Kenneth Aldape, Gelareh Zadeh. Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype. Acta neuropathologica. 2024 Apr 07;147(1):68

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 38583102

    View Full Text